Objective Cancer remains a leading cause of death and morbidity worldwide. Prostate cancer (PC) is among the most frequently diagnosed non-skin cancers. Despite major advances in the understanding of cancer biology and development of candidate therapeutic agents, there is still an urgent need of exploiting innovative chemotypes and disrupting novel signalling pathways. Evidence suggests that targeted therapies may provide an original means of selectively modulating diseased prostate cells. Herein we propose the validation and devlopment of an unprecedented approach to tackle PC, addressing the overexpressed transient receptor potential vanilloid channel V1 (TRPV1) with ligand-drug conjugates. This strategy provides a pioneering technological advance by aiming at the disruption of calcium signalling, while selectively targeting cancer cells for the delivery of cytotoxic payloads. The approach will additionally yield chemical probes for studying TRPV1 biology and for whole-animal optical imaging of TRPV1-overexpressed cancer cells. Fields of science medical and health sciencesclinical medicineoncologyprostate cancermedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural scienceschemical sciencesinorganic chemistryalkaline earth metalsnatural sciencesphysical sciencesopticsmicroscopymedical and health scienceshealth sciencespersonalized medicine Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2016 - Individual Fellowships Call for proposal H2020-MSCA-IF-2016 See other projects for this call Funding Scheme MSCA-IF-EF-ST - Standard EF Coordinator INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES Net EU contribution € 160 635,60 Address Avenida prof egas moniz 1649 028 Lisboa Portugal See on map Region Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
